Founder & CEO
City: Salt Lake City
Country: United States
Year Established: 2012
Additional Details: The company has received $2.8M non-dilutive funding from NSF, NIH, UTAH and $2.6M from investors with seed round led by Fusion Fund. The company has lined up customers with champions in top 10 pediatric hospitals, 2 IRBs in process and pilots planned in 1H 2020. Core patents are issued with 3 in process.
Financing Status: Currently raising money
Financial Round: Series A
Regulatory/Development Status: FDA 510(k) Cleared. Broad indication in adult and pediatrics.
Revenue (Past Year): Private
Sales Projection (5 Years from Now): $22M in 2022
Additional details: nView medical is a surgical company with breakthrough technology. Its first product, nView s1, is FDA cleared with four patents issued or filed. By leveraging AI and GPU/cloud computing nView s1 provides 3D images faster, with less radiation. Pilots are expected in 1H 2020. nView is seeking an $8M series-A raise in 1H 2020. The company strategy is to win in the pediatric beachhead before expanding into the adult market with offerings in imaging, navigation and robotics. nView targets an exit to strategics, with its closest comparable being Mobius imaging and Cardan robotics sold to Stryker in 2019 for $500M.